| Literature DB >> 31390583 |
Deborah K Armstrong1, Ronald D Alvarez2, Jamie N Bakkum-Gamez3, Lisa Barroilhet4, Kian Behbakht5, Andrew Berchuck6, Jonathan S Berek7, Lee-May Chen8, Mihaela Cristea9, Marie DeRosa10, Adam C ElNaggar11, David M Gershenson12, Heidi J Gray13, Ardeshir Hakam14, Angela Jain15, Carolyn Johnston16, Charles A Leath16, Joyce Liu17, Haider Mahdi18, Daniela Matei19, Michael McHale20, Karen McLean21, David M O'Malley22, Richard T Penson23, Sanja Percac-Lima23, Elena Ratner24, Steven W Remmenga25, Paul Sabbatini26, Theresa L Werner27, Emese Zsiros28, Jennifer L Burns29, Anita M Engh29.
Abstract
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.Entities:
Mesh：
Year: 2019 PMID： 31390583 DOI： 10.6004/jnccn.2019.0039
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908